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ABSTRACT The rate of change of surface pressure, p, in a Langmuir trough following the deposition of surfactant suspen-
sions on subphases containing serum, with or without polymers, is used to model a likely cause of surfactant inactivation in vivo:
inhibition of surfactant adsorption due to competitive adsorption of surface active serum proteins. Aqueous suspensions of
native porcine surfactant, organic extracts of native surfactant, and the clinical surfactants Curosurf, Infasurf, and Survanta
spread on buffered subphases increase the surface pressure, p, to ;40 mN/m within 2 min. The variation with concentration,
temperature, and mode of spreading conﬁrmed Brewster angle microscopy observations that subphase to surface adsorption of
surfactant is the dominant form of surfactant transport to the interface. However (with the exception of native porcine surfactant),
similar rapid increases in p did not occur when surfactants were applied to subphases containing serum. Components of serum
are surface active and adsorb reversibly to the interface increasing p up to a concentration-dependent saturation value, pmax.
When surfactants were applied to subphases containing serum, the increase in p was signiﬁcantly slowed or eliminated.
Therefore, serum at the interface presents a barrier to surfactant adsorption. Addition of either hyaluronan (normally found in
alveolar ﬂuid) or polyethylene glycol to subphases containing serum reversed inhibition by restoring the rate of surfactant
adsorption to that of the clean interface, thereby allowing surfactant to overcome the serum-induced barrier to adsorption.
INTRODUCTION
Lung surfactant is a mixture of lipids (primarily dipalmitoyl-
phosphatidylcholine) and four lung surfactant speciﬁc pro-
teins (SP-A, B, C, and D) that line the interior of the lung
alveoli. Lung surfactant lowers the interfacial tension in the
lungs, thereby insuring minimized work of breathing and
uniform lung inﬂation (1). The absence of lung surfactant
due to prematurity leads to neonatal respiratory distress syn-
drome (NRDS). In NRDS, the lack of functional surfactant
results in a progressive failure of the lungs, which is mani-
fested clinically by atelectasis (collapsed alveoli), decreased
lung compliance (stiff lungs), decreased functional residual
capacity (a measure of the amount of air left in the lungs after
exhalation), systemic hypoxia (oxygen starvation), and lung
edema (protein rich ﬂuid in the lungs) (1–3). Treating NRDS
with currently available replacement surfactants has signif-
icantly reduced neonatal mortality in developed countries
(1,3). However, there are certain cases, meconium aspiration
syndrome being one example, in which surfactant therapy is
less effective because surfactant loses the ability to reduce
surface tension and is said to be ‘‘inactivated’’ (3–6).
Surfactant inactivation is likely one cause of acute
respiratory distress syndrome (ARDS), which affects both
adults and children. ARDS has an incidence of 150,000 cases
per year (United States) and a mortality rate of ;30%
(3,7,8). The pathophysiology of ARDS involves injury to
the alveolar-capillary barrier, lung inﬂammation, atelectasis,
surfactant dysfunction, and intrapulmonary shunting. The
disorder typically appears rapidly within 12–24 h of an
identiﬁable clinical event and may be due to direct lung
injury, such as gastric content aspiration, pneumonia, near-
drowning, toxic gas inhalation, or chest/lung trauma. In
addition, ARDS may be associated with systemic processes
such as sepsis, nonthoracic trauma, acute pancreatitis, major
surgery, multiple blood transfusions, fat embolism, or shock.
No speciﬁc therapy for ARDS currently exists. Although
ARDS has a more complicated pathology than the simple
absence of surfactant, ARDS shares many NRDS symptoms
such as diminished lung compliance, marked restriction of
lung volumes, and profound hypoxemia. Hence, it was
hoped ARDS might respond favorably to surfactant replace-
ment therapy. However, clinical trials with the most effective
formulations used in NRDS yield gains in ARDS patients
that are both modest and transient (3,7,9–12), suggesting that
ARDS involves not only a lack of functional surfactant, but
an inactivation of the endogenous or exogenous surfactant
present.
There are many ways surfactant can be inactivated at
various points in the surfactant life cycle; from transcription
and protein translation, during multivesicular and lamellar
body formation in the type II cell (13,14), secretion into the
hypophase liquid layer, transformation from lamellar bodies
to tubular myelein to membrane vesicles (3), transport
through subphase to the alveolar interface, reuptake by type
II cells or macrophages, or losses due to transport out of the
alveoli to the airways (3). Inactivation can be slow (enhanced
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degradation from increased volume changes), permanent
(from lipase or protease activity), or rapid and reversible. In
ARDS and other acute lung injuries, the inactivation is rapid
and likely reversible and may explain why exogenous
surfactant does not have the dramatic immediate effect when
treating adult lung injuries seen when treating premature
newborns with surfactant deﬁciency (NRDS) (8,11,15–22).
In ARDS, increased concentrations of serum proteins in the
alveolar hypophase are a likely cause of rapid inactivation;
albumin concentrations in ARDS alveolar ﬂuid may reach
100 mg/ml, with an average concentration reported by
Ishizaka and co-workers of 25 mg/ml (23). Surfactants may
be made resistant to serum and other inactivating substances
in the alveolar spaces during acute lung injury (24–28); a
common ﬁnding is that increased concentrations of surfac-
tant and increased fractions of surfactant speciﬁc proteins
reduce inactivation by serum (20,29–34). A more recent and
surprising ﬁnding is that hydrophilic, nonadsorbing poly-
mers added to aqueous mixtures of organic surfactant ex-
tracts (which contain SP-B and SP-C, but not SP-A) reduces
rapid inactivation by serum, meconium, albumin, and other
substances both in vitro and in vivo (4–6,35–42). The added
polymers allow these surfactants to better mimic fully con-
stituted native mammalian surfactant, which appears to be
more resistant to inactivation than clinical organic solvent-
extracted surfactants.
Diemel and co-workers have recently shown the utility of
studying spreading rates of various surfactant preparations
applied to the surface of a buffered subphase in a Langmuir
trough to examine surfactant inactivation (43). The change of
surface pressure, p, as a function of time after surfactant
deposition gave an indication of the degree of surfactant
inhibition after addition of albumin (used as an inactivat-
ing agent) to the subphase. The method models tracheal
instillation of surfactants for treatment of neonatal or adult
respiratory distress syndrome. Using this technique, we have
studied a variety of surfactants applied to subphases that
include serum and/or polyethylene glycol ((PEG) 10 kDa) or
hyaluronic acid ((HA) 1240 kDa). Brewster angle micros-
copy (BAM) was used to visualize the surfactant ﬁlm during
adsorption and spreading.
When clinical surfactants that are approved for use in the
United States for treatment of neonatal respiratory distress
syndrome (Infasurf, Survanta, or Curosurf) are spread as
aqueous dispersions, adsorption from the subphase is the
major route for surfactant accumulation at the interface.
Clinical surfactants adsorb quickly (,100 s) to a clean
interface, in a concentration and temperature-dependent
manner up to the equilibrium spreading pressure, pe, (;40–
45 mN/m), in a very similar fashion to native porcine
surfactant. Adding serum to the subphase before surfactant
deposition caused serum components to reversibly adsorb
to the interface, leading to a serum concentration-dependent
surface pressure that saturates at pmax ; 20 mN/m (19,44).
Surfactant adsorption was signiﬁcantly slowed for all the
clinical surfactants at surface pressures below pmax. Above
pmax, surfactant adsorbed at roughly the same rate as to
a clean interface. From these experiments, the reduced rate
of surfactant adsorption caused by the need to displace the
serum proteins from the interface is one origin of rapid
surfactant inactivation. As shown in the companion article
(45), the surface-active proteins in serum create a steric and/
or electrostatic barrier (46,47) to surfactant adsorption below
pmax. The surfactant aggregates remain in suspension; the
surfactant simply cannot reach the interface due to the serum
protein barrier. Above pmax, the serum proteins are displaced
from the interface by surfactant, and there is no longer a
signiﬁcant resistance to surfactant adsorption from the sub-
phase. Hence, to reverse inactivation, it is necessary to either
remove sufﬁcient serum from the subphase or to enhance
surfactant adsorption to displace the surface-active serum
components from the interface.
Adding 5 wt% PEG or 0.125 wt% HA to the subphase
restored the rate of clinical surfactant adsorption with serum
in the subphase to that of the clean subphase, effectively
reversing this form of surfactant inactivation. Native porcine
surfactant containing SP-A was not inactivated by serum;
sufﬁcient SP-A may have the same effect as adding polymer
to the subphase. The enhanced adsorption of surfactant in the
presence of hydrophilic polymers can be explained using
a simple ‘‘depletion attraction’’ (42,48–52) model described
in the companion article. The surfactant aggregates are
pushed toward the interface by an osmotic pressure induced
by the exclusion of the polymer from the ‘‘excluded volumes’’
of the surfactant aggregates and the interface. The depletion
attraction is sufﬁciently strong that it can overcome the
electrostatic and steric repulsion imposed by the serum. The
model also explains why high molecular weight, anionic
polymers like HA can reverse inhibition at lower weight
fractions than neutral, lower molecular weight polymers like
PEG. Lower concentrations of higher molecular weight
polymers would be beneﬁcial in vivo to minimize edema due
to osmotic imbalance in the lungs (42,53,54). The model also
suggests that the SP-A and hyaluronan normally present
in the alveolar hypophase may act to accelerate surfactant
adsorption under normal conditions and may allow lower
surfactant concentrations to be used in treatments.
METHODS
Materials
Infasurf (Forest Pharmaceuticals, St. Louis, MO) was purchased from the
hospital pharmacy at University of California, San Francisco. Survanta
(Abbott Laboratories, Columbus, OH) was obtained from the San Francisco
General Hospital nursery. Curosurf was purchased from Dey Laboratories
(Napa, CA). Serum was obtained from healthy laboratory volunteers and
refrigerated until use. Differences in inactivation were not seen with sera
from different volunteers. Protein content of sera was 6.8 g/dl. Polyethylene
glycol (10 kDa), hyaluronic acid (1240 kDa), and bovine serum albumin
were obtained from Sigma (St. Louis, MO). HA (250 and 100 kDa) was a gift
from GlycoMed Research (New York, NY).
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Native surfactant from slaughtered adult pigs (obtained from Matadero
Municipal, Pozuelo de Alarcon, Madrid, Spain) was prepared by lavaging
the lungs with ice-cold 0.9% NaCl buffer. Saline (2.5 liters) was introduced
in aliquots into the trachea and withdrawn. The recovered lavage ﬂuid was
centrifuged at 10003 g for 5 min to remove debris, then again in 0.9% (w/v)
NaCl, at 105,0003 g for 1 h. The supernatant was discarded and the pellets
were combined and homogenized in 24 ml 16% NaBr and 0.9% NaCl. To
form discontinuous density gradients, 4 ml of the homogenate was put into
each of six tubes, and then 6 ml of NaBr (13% in 0.9% saline) was layered
into each tube, and a ﬁnal layer of 2.5 ml of 0.9% NaCl was added. These
tubes were centrifuged in a swinging bucket rotor at 120,000 3 g for 2 h at
4C. The lipid bands were removed, rehomogenized in 0.9% saline, and
centrifuged (105,000 3 g for 1 h). Pellets were placed in buffer or distilled
water and centrifuged a second time. Lipid phosphorus (55) was measured
and the pellets were stored at 70C until further use. From one adult pig,
;200 mg of surfactant was recovered. Native surfactant extract was
prepared by adding 1 ml of surfactant (;90 mg phospholipid) in saline to
a mixture of 2 ml methanol and 1 ml chloroform; the surfactant lipids and
hydrophobic proteins were extracted into the organic phase (56).
Methods
Surfactant spreading was done either at 24–25C or 34–37C using a tem-
perature-controlled trough with a surface area of 228 cm2 (Kibron, Helsinki,
Finland) and a depth of ;1 mm. The surface pressure was measured by the
pull of the ﬁlm on a metal wire contacting the interface. The distance
between the point of application of surfactant and the pressure sensor was
27 cm. The subphase volume was ;30 ml. Three or more measurements
using at least two different vials or batches of each surfactant were carried
out and compared, with standard deviations of ;5%, although the ﬁgures
show representative results from single experiments. The standard buffer
was either 2.5 mM HEPES or 2.5 mM Tris base, with 0.9% NaCl and
2.5 mM CaCl2 adjusted to a pH of 7.0. The as-received surfactants were
diluted with the same buffer to 15 mg/ml and mixed by vortex immediately
before use (5 s 3 6 over 1 min). Unless otherwise indicated, the surfactant
suspensions were applied by micropipette in one drop to the surface (total
volume 7 ml; 15 mg/ml; 105 mg total surfactant). The volume of applied
material was ﬁxed at 7 ml and the surfactant was applied to the interface at
25 s (on the horizontal axis) for all experiments, unless otherwise speciﬁed.
Plotting in this way shows that the subphases with different additives had
different initial surface pressures.
For experiments using polymers, the appropriate amount of PEG or HA
were mixed in the same buffer until the solution was clear. HA in buffer was
sometimes heated to 50C for 1 h for complete solubilization. The standard
concentration of PEG was 5% w/v, and HA was 0.125% w/v, based on prior
in vitro and in vivo work (4,36,37,57). Human serum from laboratory
volunteers, diluted to 1–10 ml/ml in buffer, was used as a nonspeciﬁc
inhibitor. These concentrations of serum are similar to those found to reduce
surface activity of surfactants in a pulsating bubble surfactometer at 37C
(4,36,37,57). Albumin concentrations in ARDS alveolar ﬂuid may reach
100 mg/ml, with an average concentration reported by Ishizaka and co-
workers of 25 mg/ml (23). Hence, the concentrations used here are signiﬁ-
cantly lower than typically found in ARDS patients. In certain experiments,
a ﬁxed amount of serum was added to the subphase as described. In other
experiments, sufﬁcient serum was added to the subphase to obtain a surface
pressure from 10–20 mN/m after 60 s. The subphase temperature was mea-
sured with a Barnant thermocouple (Barrington, IL) and maintained with a
temperature-controlled water circulator.
Brewster angle microscopy of the surface was carried out on a custom,
temperature-controlled Langmuir-Wilhelmy balance (58–60). A p-polarized
He-Ne laser is the light source, which was directed at the surface at an angle
of 53.1 relative to vertical (the Brewster angle for water). At the Brewster
angle, water (buffer) does not reﬂect any light; all of the incident light is
transmitted into the water. However, if the interface is covered by any
material with a refractive index different from water (or buffer), light is
reﬂected and detected by a CCD camera. The intensity of reﬂected light
depends on thickness of surfactant material and the variation in refractive
index. Sequential images (30/s) were collected for 2 min from the time
surfactant was applied to the surface. Images were collected in mpeg format
for analysis by VirtualDub 1.5 (www.virtualdub.org) and PhotoShop 6.0.
Magniﬁcation was constant with a ﬁeld of view of 872 3 946 mm.
RESULTS
Fig. 1 a shows the effect of spreading different amounts of na-
tive porcine surfactant on a buffered subphase at 24C. The
rate of surface pressure increased roughly exponentially with
time up to a limiting value that depends on surfactant con-
centration. Increasing the surfactant concentration increased
the maximum surface pressure from,5 mN/m (35 mg) to 25
mN/m (70 mg) to 40 mN/m (140 mg). The maximum surface
pressure saturated at;40mN/m for surfactant concentrations
$100 mg, which is consistent with the equilibrium spreading
pressure, pe, measured by other techniques (3). The con-
centration dependence and the amount of time (;100 s)
required to reach pe (compare to Fig. 4 b), suggests that the
primary mode of surfactant accumulation at the interface is by
adsorption of surfactant aggregates from the subphase.
Surfactant spread as a molecular solution from organic
solvent reached pe in seconds and the rate of surface tension
reduction was relatively independent of the surfactant con-
centration. The spreading solvent keeps the surfactant at the
interface so that there is nothing to adsorb from the subphase.
FIGURE 1 (a) Whole porcine surfactant (7 ml aqueous suspensions;
different concentrations) applied to a clean subphase (24C) at 25 s (d
140 mg; s 70 mg ;; 35 mg total surfactant). Increasing the amount of sur-
factant increased the maximum surface pressure up to a limiting concentra-
tion of ;100 mg, at which the maximum surface pressure saturated at the
equilibrium spreading pressure of the surfactant, ;40 mN/m (3). No
differences in the maximum surface pressure were found between 105 mg
(the amount used in most of the following results) and the 140 mg shown
here. (b) Equal amounts and volumes (15 mg/ml; 7 ml; 105 mg total sur-
factant) of native whole porcine surfactant (d) and an aqueous suspension of
organic extract of whole porcine surfactant (lyophilized and taken up in
standard buffer) (h) applied to clean subphase (24C) at 25 s. Minimal
differences are seen between the two preparations. This suggests that SP-A
and SP-D, the main hydrophilic proteins in lung surfactant that are removed
by solvent extraction, are not essential to surfactant adsorption to a clean
interface.
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Fig. 1 b compares the same amounts of native porcine
surfactant in aqueous buffer versus a lyophilized chloroform/
methanol organic extract of porcine surfactant resuspended
in aqueous buffer. Similar results were obtained; both samples
caused rapid increases in surface pressure to pe; 40 mN/m.
The hydrophilic proteins SP-A and SP-D are not extracted
into the chloroform-methanol (61). The close correspon-
dence between the spreading rates and maximum surface
pressure shown in Fig. 1 b shows that SP-A (or SP-D) is not
essential to the rate of spreading or net amount of material
adsorbed on a clean subphase.
Fig. 2 a shows a comparison at 37C between the ad-
sorption rates of the three commonly used clinical surfac-
tants: Curosurf (porcine lung mince extract), Survanta (bovine
lung mince extract), and Infasurf (calf lavage extract). As for
the native surfactant, the surface pressure rose exponentially
to the equilibrium spreading pressure, pe. Curosurf consis-
tently increased the surface pressure faster and to a higher pe
than Infasurf or Survanta when applied in this fashion. The
clinical surfactants adsorb similarly to both native and ex-
tracted native surfactant on a clean subphase (Fig. 1).
Fig. 2 b shows the effect of subphase temperature on
the spreading of Curosurf. The spreading rate increased with
increasing temperature, but the maximum spreading pres-
sure was the same for all temperatures. The viscosity of
the Curosurf suspensions, ;1.3 centipoise, is similar from
15–37C (62), and does not differ signiﬁcantly from that
of saline, hence the diffusivity of the Curosurf aggregates
should also be similar at all temperatures. However, the
surface viscosity of the Curosurf ﬁlm decreases with in-
creasing temperature, so it is likely that the greater interfacial
ﬂuidity of the lipids at higher temperature (63–66) is
responsible for the increase in the spreading rate with tem-
perature. However, pe does not appear to change much with
temperature.
Fig. 3 shows the progressive decrease of the rate of ad-
sorption of Curosurf with increasing concentrations of sub-
phase serum. Serum contains a number of hydrophilic, water
soluble proteins that are surface active (19,44). Even before
surfactant is added, increasing the serum concentration causes
an increase in the surface pressure to;10 mN/m for 1.7 ml/ml
serum. Like many soluble, surface-active amphiphiles such
as detergents and lysolipids (19,67), serum has a subphase
concentration-dependent surface pressure that saturates at
a maximum value, pmax. Increasing the serum concentration
above;3 ml/ml serum does not increase the surface pressure
above ;20 mN/m. Krishnan and co-workers (44) have
measured pmax for human serum and many of the proteins
present in serum, such as albumin, hemoglobin, thrombin,
IgG, IgM, etc. and have found a rather narrow range for the
maximum surface pressure, pmax, of 20–25 mN/m. Most of
the proteins in serum reduce the surface tension by;20mN/m
at the saturation concentration, independent of the details of
the protein structure, molecular weight, or function (44).
The increase in surface pressure on addition of Curosurf to
the subphases containing serum was signiﬁcantly slower at
surface pressures below pmax than for a serum-free interface
(Fig. 3). The time required for Curosurf to reach pmax in-
creased with serum concentration. However once pmax was
FIGURE 2 (A) Curosurf (,), Infasurf (s), and Survanta (h) (15 mg/ml;
7 ml; 105 mg total surfactant) spread on a clean subphase at 37C at 25 s.
Curosurf consistently increased the surface pressure faster and to a higher
value than Infasurf or Survanta when applied in this fashion. Infasurf was
intermediate in both spreading rate and maximum surface pressure. (B)
Effect of subphase temperature on the spreading of Curosurf (15 mg/ml; 7ml;
105 mg total surfactant) on a clean subphase. (; 34C; d 24C; s 15C).
Subphase temperature increased the rate of surfactant spreading, but not the
equilibrium surface pressure.
FIGURE 3 Curosurf (15 mg/ml; 7 ml; 105 mg total surfactant) applied
to buffers (24C) with increasing concentrations of serum. (d no serum; s
0.4 ml serum/mL buffer; ; 0.8 ml serum/mL buffer; , 1.7 ml serum/mL
buffer.) Increasing the serum concentration increased the buffer surface
pressure (data before 25 s). The increase in surface pressure after addition of
Curosurf at 25 s was slow below ;20 mN/m (dotted line), and was propor-
tional to the serum concentration. Above;20 mN/m, the increase in surface
pressure was similar to that of the serum-free surfaces (see Figs 1 and 2). The
critical surface pressure at which the rates change is roughly equal to the
maximum surface pressure, pmax, of a subphase containing a saturation con-
centration of serum, ;20 mN/m (19,44). The data suggest that as the sur-
factant adsorbs, the surfactant compresses the serum components at the
interface up to pmax, at which the serum components are squeezed out from
the interface back into the subphase. At higher serum concentrations in the
subphase, more serum is adsorbed to the interface (44), and it takes longer
for surfactant to adsorb and raise the surface pressure to pmax.
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reached, the increase in surface pressure was similar to that
of the serum-free surfaces and was independent of the serum
concentration (see Fig. 2). The data suggest that as the sur-
factant adsorbs, it ﬁrst concentrates the serum proteins so that
the surface pressure increases to pmax. Further surfactant
adsorption then starts to displace the serum proteins from the
interface; as the surface pressure increases, the equilibrium
partition of serum proteins is altered so that the proteins
return to the subphase. At higher serum concentrations in the
subphase, more serum is adsorbed to the interface up to
saturation (44), and it takes longer for surfactant to adsorb
and raise the surface pressure to pmax. Above pmax, the
adsorption rate is similar to the rates shown in Figs. 1 and 2;
the surfactant adsorbs at a similar rate as to a ‘‘clean’’ serum-
free, surfactant-coated interface. For sufﬁciently high serum
subphase concentrations, the clinical surfactants by them-
selves never increase the surface pressure above pmax (see
Figs. 4–7).
When aqueous Curosurf was applied on buffer containing
serum (see Fig. 4 a), only minimal increases in surface pres-
sure were observed. Before application of the surfactant, the
serum-containing buffer had a surface pressure of;12mN/m.
As in the higher serum concentrations in Fig. 4, application of
Curosurf did not change the surface pressure signiﬁcantly,
suggesting that a sufﬁciently high density of serum proteins at
the interface prevents adsorption of Curosurf. However, when
native porcine surfactant containing the hydrophilic proteins
SP-A and SP-D was applied at 200 s after Curosurf had been
applied to the buffer with serum, a rapid increase in surface
pressure to ;40 mN/m occurred. The rate of increase was
similar to that of whole surfactant on a clean interface
(Fig. 1 b). If additional aqueous Curosurf was added at 200 s
instead of native porcine surfactant, no increase in surface
pressure was seen (data not shown).
However, Fig. 4 b shows that aqueous suspensions of
organic extracts of porcine surfactant added to the subphase
(at 25 s) do not cause a similar rise in surface pressure on
a serum-containing subphase. The surface pressure does not
rise above pmax, suggesting that the extracted surfactant
cannot displace the serum proteins from the interface. The
main difference between the composition of organic extract
and that of porcine surfactant is the presence of the hydro-
philic proteins SP-A and SP-D, which apparently assist in
surfactant adsorption from the subphase. In addition to the
presence of these proteins, surfactant adsorption could also
be much more efﬁcient via the formation of different bilayer
aggregate structures such as lamellar bodies and tubular
myelin surfactant formed by native surfactant (see Fig. 7),
which are likely different than the structures formed by the
reconstituted organic extracts (62).
However, spreading the porcine organic extract surfactant
directly at the interface in chloroform/methanol solution (at
200 s) causes the surface pressure to rise immediately to the
equilibrium spreading pressure. This conﬁrms that surfactant
inactivation is primarily caused by a decrease in the rate of
surfactant adsorption from the subphase due to the presence
of the surface-active components of serum. If surfactant can
reach the interface, either due to the particular structure of the
native complexes, including the presence of SP-A in the
subphase (Fig. 4 a), or by directly applying the surfactant to
the interface via an organic solvent (Fig. 4 b), serum has little
effect on the rate of change of surface pressure or the equi-
librium spreading pressure.
Serum inactivation occurred for all aqueous surfactants
(with the exception of whole native porcine surfactant)
including suspensions of Infasurf, Curosurf, Survanta, and
organic extract of porcine surfactant at both 24 and 34–
37C, although greater amounts of serum were required at
34–37C to induce inactivation (700 vs. 210 mg serum pro-
teins per milliliter of buffer). The amount of serum needed
for inactivation for the different surfactants varied as
Survanta , Curosurf , Infasurf , surfactant extract ,
whole surfactant. In other words, whole surfactant was the
least susceptible to serum inactivation. On the other hand,
any of the surfactants that were lyophilized and resuspended
in 2:1 chloroform methanol and deposited from organic
solvent caused a rapid rise in surface pressure to;40 mN/m,
even if the subphase contained serum. This conﬁrms that
this form of surfactant inactivation is caused by a decrease in
FIGURE 4 (a) Aqueous Curosurf (15 mg/ml; 7 ml; 105 mg total
surfactant) deposited at 25 s on a subphase containing serum (;). The
initial surface pressure due to the serum was ;12 mN/m before adding
Curosurf. There was a very slow and gradual increase in surface pressure on
addition of the surfactant. At 200 s (right arrow), whole aqueous porcine
surfactant (15 mg/ml; 7 ml; 105 mg total surfactant) was applied to the
surface and a rapid rise in surface pressure to;40 mN/m was seen. The rate
of change of the surface pressure was similar to that on a clean interface (Fig.
1 b). If a second application of Curosurf was added at 200 s instead of whole
porcine surfactant, no increase of surface pressure occurred (data not
shown). (b) Whole porcine surfactant solvent extract, lyophilized and
resuspended in aqueous buffer (15 mg/ml; 7 ml; 105 mg total surfactant) was
applied at 25 s (left arrow) on serum (d) containing buffer (initial surface
pressure, 18 mN /m). No change in surface pressure was observed. At 240 s,
the same surfactant extract in organic solvent (15 mg/ml; 7 ml; 105 mg total
surfactant) was applied (right arrow), leading to an almost instantaneous rise
in surface pressure to ;40 mN/m. Applying the surfactant from solvent
bypasses the serum proteins at the interface, allowing for fast decrease in
surface pressure. This also conﬁrms that the serum proteins primarily inhibit
the adsorption of surfactant from the subphase, rather than interacting
speciﬁcally with the surfactant.
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the rate of surfactant adsorption from the subphase due to the
presence of surface-active serum components at the air-water
interface.
Previous work has shown that hydrophilic polymers can
also reverse inactivation both in vitro and in vivo (4–6,
35–42). Fig. 5 a (Infasurf) and Fig. 5 b (Curosurf) show that
when either HA or PEG was added to the serum-containing
subphase, a rapid increase in surface pressure to ;40 mN/m
occurred after addition of the aqueous suspensions of sur-
factant. The standard concentrations of 5% w/v 10 kDa PEG
and 0.125% w/v of 1240 kDa HA were based on prior in
vitro and in vivo work (4,36,37,57).
Fig. 5 shows that when either aqueous Infasurf (Fig. 5 a)
or Curosurf (Fig. 5 b) was added to serum-containing sub-
phases, little to no increase in surface pressure occurred and
the maximum surface pressure was set by the serum at
;pmax. HA by itself does not affect the surface pressure of
the subphase without serum (the HA curve begins from a
surface pressure of nearly zero), or the subphases with serum.
However, HA does accelerate the adsorption of Infasurf for
both serum-containing and serum-free subphases (compare
to Fig. 2). For Infasurf, both HA and PEG lead to similar
increases in the rate of surfactant adsorption. For Curosurf
(Fig. 5 b) on subphases that also contained HA or PEG, the
surface pressure increased to;40 mN/m, either very quickly
for PEG, or after a short induction time for HA. This
difference in initial adsorption rate may be related to the
higher initial serum surface pressure of ;15 mN/m for HA
compared to;12 mN/m for the PEG experiments. As in Fig.
4, once the surface pressure exceeded pmax of the serum, the
rate of change of surface pressure increased dramatically
and was similar to that for a clean interface (Figs. 1 and 2).
The equilibrium surface pressure of Curosurf was not signiﬁ-
cantly changed by the presence of PEG or HA. Porcine
surfactant extract (data not shown) and Survanta (data not
shown) also show an increase in the rate of adsorption by
both PEG and HA. Reduction of serum inactivation in the
presence of subphase polymers was found both at 24C and
at 35–37C. Again, the equilibrium spreading pressure of
Curosurf and Infasurf were not affected by HA or PEG. It
appears that the polymers do not interact speciﬁcally with
either the serum or particular surfactants and alter the surface
pressure by themselves. Instead, the polymers decrease the
barrier to adsorption and thereby accelerate the transport of
whatever surfactant is available in the subphase to the interface.
Brewster angle microscopy
BAM images showed rapid lateral motion immediately
following application of Curosurf to the subphase (Fig. 6, top
row). BAM reveals differences in the local refractive index
at the interface due to variations in monolayer density, ori-
entation, structure, etc. Larger objects ﬂoating at or near the
interface that scatter or reﬂect light are also visible (60). The
rate of lateral spread slowed as surface pressure increased,
consistent with a simple surface tension driven ﬂow (68). A
rough estimate of the ﬂow velocity was made by measuring
the speed of various structures as they moved across the ﬁeld
of view (;1000 mm or 1 mm). For example, the rate of
lateral spreading of an individual white domain observed
after spreading Curosurf was 7 cm/s at a surface pressure of
4 mN/m (;5 s after applying surfactant to the surface);
0.7 cm/s at a pressure of 18 mN/m (30 s after applying sur-
factant); and, 0.3 cm/s at a pressure of 27 mN/m (60 s after
applying surfactant). Fig. 6 a shows a variety of bright and
dark spots in the image corresponding to Curosurf aggregates
trapped at or near the interface (58,60). Such structures were
not evident on serum-containing subphases (Fig. 6 b) in
which the surface pressure remained low after Curosurf
addition. No lateral spreading of Curosurf was evident with
serum in the subphase; it is likely that the serum proteins
occupying the surface prevented the adsorption of surfactant.
In addition, adsorption of serum over the entire interface
lowered the surface pressure (to ;pmax) and reduced the
surface tension gradient driving the spreading of surfactant.
However, when serum and PEG or HA were both added to
the subphase, lateral spreading rates and the number of
surface structures were similar to those obtained on buffer
without serum (Fig. 6 c). Results were similar for other
clinical surfactants on buffer and when HA was present in
the buffer with serum (42). Native porcine surfactant, which
was not inactivated by serum, showed a high density of
surfactant aggregates near the interface for both clean
subphases and serum-containing subphases (Fig. 6, d and e).
FIGURE 5 (a) Infasurf (15 mg/ml; 7 ml; 105 mg total surfactant) applied
to different subphase mixtures at 24C at 25 s:dHA-buffer;s serum1HA
(0.125%); , serum 1 PEG (5%); ; serum alone. HA by itself does not
raise the surface pressure of the subphase; however, serum alone or serum
with HA or PEG raises the subphase surface pressure to;12 mN/m at these
concentrations. HA and PEG do not alter the serum surface pressure in
the absence of surfactant. However, HA in the subphase accelerates the
adsorption of Infasurf both with and without serum (compare to Fig. 2) in
the subphase. With serum in the subphase, both HA and PEG prevent inhibi-
tion. (b) Curosurf (15 mg/ml; 7 ml; 105 mg total surfactant) applied at 25 s
to subphase containing serum alone (;), or serum 1 HA (0.125%) (s), or
serum 1 PEG (5%) (,), at 24C. The rate of adsorption to the equilibrium
spreading pressure is increased with both PEG and HA. PEG induced a rapid
adsorption whereas HA showed a slow adsorption below pmax of the serum
followed by a rapid adsorption for surface pressures above pmax.
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DISCUSSION
In normal lungs, after secretion of surfactant in the form of
multilamellar bodies from alveolar type II cells (13,69,70),
surfactant must unpack, move across the alveolar hypophase,
adsorb to the air-water interface, and then transform from
bilayer to monolayer and spread over the interface (Fig. 7 a)
(71). The primary function of lung surfactant is to vary the
surface tension at the alveolar surface with changes in lung
volume (hence alveolar surface area), the effects of which are
to minimize the work of breathing, maintain a reservoir of
air at end-expiration, prevent pulmonary edema, and allow
equal inﬂation and deﬂation of different size alveoli. Simi-
larly, aqueous mixtures of surfactant, introduced into the
airway of a patient with lung disease, must travel to the
periphery of the lung, adsorb, and spread to cover the air-
liquid interface, despite the presence of alveolar inhibiting
substances (Fig. 7 b). For both normal and exogenous sur-
factant, adsorption through the liquid subphase is the
primary route of surfactant accumulation at the interface.
The spreading assay described here is a simple and repro-
ducible method of studying surface activities of surfactants
under a variety of conditions. Our experiments show that for
surfactants deposited as aqueous suspensions, signiﬁcant
accumulation and exchange of surfactant occurs by adsorp-
tion of surfactant aggregates from the subphase. BAM
FIGURE 6 Brewster angle microscopy of the air-
liquid interface ;2 min after application of surfactant.
(a) Curosurf on clean buffer. (b) Curosurf on buffer
with serum. (c) Curosurf on buffer with serum and
PEG. With either clean buffer or buffer containing
serum and PEG, diverse surface structures are seen and
surface pressures are .35 mN/m. With serum alone in
buffer, the surface is featureless, and surface pressure
remains low. (d) Native porcine surfactant with SP-A
on clean buffer. The surface pressure is;40 mN/m. (e)
Native porcine surfactant with SP-A on a serum
containing buffer (up to 10 ml/ml at 24C). Surface
pressure is;40 mN/m. There is no apparent difference
between panels d and e suggesting that the SP-A in
native surfactant can help overcome serum inactiva-
tion. A higher density of bright structures is noted in
the experiments with native surfactant compared with
those with surfactant extracts or commercial surfac-
tants, suggesting better adsorption of native surfactant
regardless of conditions.
FIGURE 7 A model for surfactant spreading and
adsorption of surfactant. Panel b illustrates surfactant
secreted from the alveolar type II and the steps
necessary for it to form a surface layer on alveolar
subphase (in vivo): 1), secretion of multilamellar
bodies from the Type II cell is generally followed by
formation of tubular myelin surfactant; 2), the tubular
myelin surfactant spreads as individual bilayers; 3), fu-
sion and conversion of bilayers to monolayers; and 4),
lateral spreading of surfactant monolayers. Panel b
summarizes processes that may occur when aqueous
surfactant is spread on the subphase surface (spreading
in vitro): 1), deposition as aqueous suspension from
syringe; 2), surfactant aggregates suspended in the
subphase; 3), fusion and conversion of bilayers to
monolayers; 4), spreading on monolayers at the air-
liquid interface; and 5), transport of surfactant
aggregates in the subphase.
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images show a surface ‘‘twinkling’’ that looks like tiny
raindrops hitting the surface of a lake as the aggregates
approach the interface. This twinkling has been described
by Winsel and co-workers in less phenomenological (and
less poetic) terms. They studied whole human surfactant
obtained by lavage from patients with sarcoidosis (72). After
placing surfactant in subphase buffer, they aspirated the
surface and observed by BAM the reaccumulation of surface
material for times up to 1 h with surface pressures increas-
ing from 20 mN/m to 44 mN. Complex surface structures
were seen as surface pressures rose, with overall surface
reﬂectivity increasing, indicating formation of structures on
and below the surface. They state, ‘‘Frequently one can
observe a ‘particle’ approaching the surface from the sub-
phase. In the moment of appearance of the particle at the
interface, a spherical domain of ﬁlm is forming in a very
rapid way.’’
Inactivation of surfactant by capillary to alveolar leak of
serum is probably relevant to acute lung injuries. Albumin
concentrations in ARDS alveolar ﬂuid may reach 100 mg/
ml, with an average concentration of 25 mg/ml (23). In
excised rat lungs or in living rats, introduction of serum
proteins into the trachea causes changes in mechanical
behavior of the lungs consistent with surfactant inactivation
at even lower concentrations (18,73). In vitro studies show
that addition of serum to the subphase, or mixing serum with
surfactant reduces the surface activity of surfactants (3).
Serum, like lung surfactant, is surface active (44). How-
ever, unlike surfactant, the serum proteins likely responsible
for its surface activity (albumin, IgG, IgM (44)) are soluble
in the subphase and are in rapid exchange equilibrium
between the subphase and the interface. The surface activity
of serum proteins is more similar to simple, water-soluble
amphiphiles such as detergents and lysolipids (19,44,67)
than the water-insoluble lipids in lung surfactant. Increasing
the subphase serum concentration causes an increase in the
surface pressure proportional to the logarithm of the con-
centration (19,44) up to a maximum value, pmax. Krishnan
and co-workers (44) have measured pmax for human serum
and many of the proteins present in serum, such as albumin,
hemoglobin, thrombin, IgG, IgM, etc., and have found a
rather narrow range for pmax. The surface-active proteins in
serum adsorbed to the air-water interface create a steric and/
or electrostatic barrier (46,47) to surfactant adsorption.
Slowly compressing a serum-covered interface does not lead
to a signiﬁcant increase in the surface pressure; instead
serum at the interface equilibrates with serum in the sub-
phase to keep the serum surface concentration and surface
pressure roughly constant at pmax (19,44), although protein
unfolding or denaturation at the interface can lead to some
hysteresis in the surface pressure.
Our data suggest that as surfactant adsorbs, it compresses
the serum proteins at the interface up to pmax, at which point
the serum proteins likely leave the interface and are solu-
bilized in the subphase. At higher serum concentrations in
the subphase, more serum is adsorbed to the interface that
must eventually be displaced (44), and it takes longer for
surfactant to adsorb and raise the surface pressure to pmax.
Above pmax, the surfactant adsorbs to an effectively
surfactant-coated interface, and the rate of adsorption above
pmax is similar to the rates shown in Figs. 1 and 2 for serum
free interfaces. However, to raise p signiﬁcantly above pmax,
the serum at the interface must be replaced by surfactant,
a process that is slower the higher the concentration of serum
in the subphase.
For sufﬁciently high serum subphase concentrations, the
clinical surfactants never increase the surface pressure above
pmax (see Figs. 3–6) within the timescale of these experi-
ments. The slow surfactant adsorption in the presence of
serum suggests that the serum imposes an electrostatic and/or
steric barrier to surfactant adsorption from the subphase. We
cannot distinguish if the barrier to adsorption comes from
serum adsorbed to the interface or to the bilayer aggregate in
solution. However, when the surfactant is applied directly to
the interface by an organic solvent, thereby bypassing the
serum barrier to adsorption, the change in surface pressure is
instantaneous, regardless if serum is present in the subphase
(Fig. 4 b). Adding PEG or HA largely reverses this inac-
tivation by enhancing surfactant adsorption below pmax.
(35,40,74). Adding synthetic polymers to surfactants im-
proves responses to treatment in animal models of acute lung
injury (42,53,54).
The natural polymer, HA, and other glycosaminoglycans,
are secreted by alveolar epithelial cells (75,76). These mol-
ecules may interact physically with surfactant under normal
and abnormal conditions in the alveoli (13,74,77–82). Like
PEG, HA is hydrophilic and not particularly surface active
and does not appear to adsorb to surfactant bilayers or
monolayers. The unifying features of the polymers that re-
verse inactivation are: 1), they do not speciﬁcally adsorb to
surfactant aggregates; 2), they are small compared to sur-
factant aggregates (nanometers versus microns); 3), inhi-
bition reversal occurs for all surfactant and polymer mixtures
tried so far (4,35,36,40,42,57,74,83). This suggests that a
generic interaction, the so-called ‘‘depletion interaction’’ as
discussed in the companion article (45), leads to inactivation
reversal, rather than a speciﬁc interaction between particular
surfactants and polymers or between serum and polymer.
The depletion interaction results from the increased free
volume available to the polymer as the surfactant aggregates
ﬂocculate or adsorb to the interface (49–51).
CONCLUSIONS
Our spreading experiments show that serum adsorbs to the
air-water interface, which reduces the rate at which surfactants
adsorb due to a combination of steric effects and likely,
electrostatic repulsion. Less surfactant adsorption means a
slower increase in the surface pressure, and the need for
greater compression to reach the nearly zero surface tensions
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required for proper lung function. This is similar to what was
observed in our earlier work that showed respreading of
collapsed monolayers was inhibited by serum proteins (19)
or electrostatic interactions between charged lipids (47). At
the much more rapid rates at which surfactant must adsorb in
the alveoli during respiration, this can lead to much higher
surface tensions than can be accommodated by normal lung
function. Hydrophilic polymers, and the hydrophilic surfac-
tant protein SP-A, accelerate the adsorption of surfactant,
likely via a nonspeciﬁc depletion attraction as discussed in
the companion article (45). If lowering the energy barrier to
adsorption via the depletion attraction can increase the rate
of surfactant adsorption, sufﬁcient surfactant will adsorb to
quickly reach its equilibrium spreading pressure, pe. As this
is greater than the equilibrium spreading pressure of the
serum, pmax (and most other proteins present in the alveoli),
the surfactant should be able to displace the serum from the
interface and eliminate inactivation.
The depletion model may also help explain certain in vivo
structures as well. Whole, native porcine surfactant with
SP-A is less inhibited by serum than surfactants from which
SP-A has been extracted (surfactant extract, Survanta, Curosurf,
and Infasurf). SP-A is the most abundant protein in lung
surfactant and is hydrophilic and soluble, and may provide
a depletion force, similar to the hydrophilic polymers. In
vivo, surfactant is released from the type II cell as micron-
sized lung multilamellar bodies (3,13,14). On entering the
liquid layer lining the alveolus, multilamellar bodies trans-
form into tubular myelin, a structure that has a regular re-
ctangular lattice of bilayers with water layers ;50–500-nm
thick (3,69). It is generally believed that this transition re-
quires SP-A, SP-B, and calcium (3,84–86). SP-A, as well as
the other natural macromolecules in the alveolar ﬂuid (which
include HA) may induce depletion forces that increase
surfactant adsorption. The polymers added to replacement
surfactants may replicate or enhance this function of SP-A.
Native surfactant with SP-A remains the gold standard that
has not yet been duplicated by commercial or extracted
surfactants. Results indicate that current surfactants used in
therapy can be improved by addition of hydrophilic poly-
mers that promote adsorption of the surfactant to the in-
terface via a depletion force. We speculate that one of the
reasons that surfactant replacement has not worked well in
ARDS may be that serum, and other surface-active materials
not normally present in the alveolar ﬂuids, adsorb to the
interface and act as a barrier to surfactant adsorption. Insuf-
ﬁcient surfactant adsorption leads to higher surface tension in
the lungs, and subsequent difﬁculties in respiration. Addi-
tion of hydrophilic polymers that accelerate the adsorption
of surfactant to the interface, especially in the presence of
serum, may be useful to include with surfactant treatment.
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